stockrowMindWalk Holdings Corp.
HYFT Healthcare Biotechnology
MindWalk Holdings Corp.’s revenue for fiscal 2026 (year ended April 2026) was $11.3 million, down 35.9% from fiscal 2025.
- Revenue
- +19.4%
- EPS
- −80.0%
- Free cash flow
- +9.79%
- Total debt
- −10.8%
Quarter to July 2026, against a year earlier
Follow HYFT
Alert me
MindWalk Holdings Corp. (HYFT) EV/Sales
As of 6 November 2026, MindWalk Holdings Corp. (HYFT) trades at a EV/Sales of 4.1×. Over the past ten years it has ranged from 0.0× (October 2020) to 22.8× (December 2020); the current reading is higher than 47% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 4.6× | 356.53% |
| FY2025 | 1.0× | (54.29%) |
| FY2024 | 2.2× | (46.00%) |
| FY2023 | 4.1× | (27.55%) |
| FY2022 | 5.6× | (44.99%) |
| FY2021 | 10.2× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jul 2026 | 5.1× | 10.92% |
| Apr 2026 | 4.6× | (13.50%) |
| Jan 2026 | 5.3× | (2.89%) |
| Oct 2025 | 5.4× | 12.22% |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IBIO iBio, Inc. compare | −12.8× |
| CRBU Caribou Biosciences, Inc. compare | −5.0× |
| MREO Mereo BioPharma Group plc - Sponsored ADR compare | n/m |
| APLM Apollomics Inc. compare | n/m |
| HOWL Werewolf Therapeutics, Inc. compare | 2.0× |
| IMA ImageneBio, Inc. compare | 2.7× |
| HYFT MindWalk Holdings Corp. | 4.1× |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR compare | 4.9× |
| TIL Instil Bio, Inc. compare | 447× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)